Healthcare Averages 31.2x Earnings, NUTX at 2.38x, GSK 13.01x

Healthcare sector averages mediocre scores (51/100 composite) with high P/E of 31.2 and negative ROE of -17.6%, yet top stocks like NUTX (P/E 2.38, ROE 78.92%) and SIGA (P/E 7.13, ROE 43.61%) show strong value and quality.

The healthcare sector's average valuation score of 52/100, P/E of 31.2, and negative ROE of -17.6% signal a broad undervaluation amid profitability pressures. Despite these metrics, aging demographics, AI innovations, and rising M&A expectations create strong tailwinds, drawing value investors to quality stocks at a discount. This disconnect highlights potential for long-term recovery in subsectors like biopharma and medtech.

• Avg P/E of 31.2 trades at a 50% premium to S&P 500 historical norm of ~20-22, pressured by high growth expectations in biotech despite standouts like NUTX (P/E 2.38) and SIGA (P/E 7.13) offering deep value.

• Avg ROE of -17.6% sharply lags S&P 500 benchmark of 15%, signaling widespread capital inefficiency amid post-pandemic recovery, contrasted by leaders HALO (179.14%) and NUTX (78.92%).

• Avg Valuation Score 52/100 matches fair market pricing but trails sector leaders like GSK (71/100) and INCY (70/100), amid healthcare stocks underperforming S&P 500 by 48% since early 2023.

• Avg Quality Score 52/100 indicates middling fundamentals versus broader market norms, with only 10% of tracked stocks (e.g., CPRX 69/100, HRMY 67/100) exceeding 65/100 amid projected 7% EBITDA CAGR to 2028.

• 1084 stocks tracked with median market cap ~$1-5B range (e.g., TMDX $4.1B, CPRX $2.6B), dominated by mid-caps versus large-cap S&P 500 skew, as HST segments drive 9% EBITDA growth.

• Top ROE outliers average 50%+ (HALO 179%, NUTX 79%, SIGA 44%) exceed sector -17.6% by 300-1000bps and S&P 500 15% norm, highlighting biotech efficiency amid payer/provider margin recovery.

• P/B dispersion wide at 1.8-25.2 (e.g., HALO 25.2 vs GMED 1.83) versus sector avg ~4, reflecting asset-light innovators trading above historical healthcare norms of 2-3x amid AI-driven HST acceleration.

Valuation Opportunity

Healthcare sector averages a modest Valuation Score of 52/100 with P/E of 31.2, but top stocks like NUTX (73/100, P/E 2.38) and GSK (71/100, P/E 13.01) trade at deep discounts. Sector valuations hit 35-year lows relative to S&P 500 amid policy fears, now largely priced in. This suggests selective value for fundamental investors despite average scores.

Quality Standouts
While sector ROE averages -17.6%, leaders like HALO (179.14%) and NUTX (78.92%) show exceptional returns on equity. Stocks such as SIGA (ROE 43.61%, P/E 7.13) and INCY (ROE 30.39%, Valuation 70/100) combine high quality with attractive multiples. Variability highlights need for stock-picking in a low-average sector.

Recent Underperformance
Sector lagged S&P 500 with Q2 2025's worst relative return and YTD retreat of 4.1%, driven by policy rhetoric, patent cliffs, and AI/tech rotation. Despite outflows since 2023, S&P Healthcare rose only 4% vs. market's 52%. Fundamentals like cash flows persist amid dislocations.

Key Tailwinds
Innovation in obesity drugs, AI efficiencies, and M&A uptick counter headwinds, with aging demographics boosting demand. Firms mitigate

Risks via US manufacturing shifts; subsectors like MedTech link to hospital growth. Selective

Opportunities emerge as uncertainty peaks.

Healthcare sector offers value opportunities with top stocks like NUTX, GSK, and INCY showing strong valuation scores (70-73/100), low P/Es (2-15), and high ROEs (28-79%), far exceeding sector averages. Amid low valuations and policy clarity, watch M&A acceleration, Q1 2026 earnings, and regulatory/FDA updates as catalysts for re-rating and biotech recovery.